ભારતમાં GLP-1 થેરેપી માટે કૌન પાત્ર?
Eligibility સાધારણ BMI checklist નહીં. ICMR/RSSDI South Asian thin-fat, central obesity, early diabetes family history. Criteria સમઝકર consultation તૈયાર, decline ક્યોં, self-diagnose/unregulated sellers નહીં. Scale સે documentation/honest lifestyle ઇતિહાસ.
Short answer
RSSDI: T2D first-line અપર્યાપ્ત. Obesity: BMI ≥27.5 યા ≥25 comorbidity ICMR. Lifestyle trial પહલે. Physician contraindications, affordability, monitoring—Kesho પાત્રતા નહીં તય કરતા. Labs, waist, lifestyle docs લાએँ.
Key takeaways
- •T2D indication high BMI not required—RSSDI HbA1c unmet despite metformin/lifestyle GLP-1 RA support.
- •Obesity ICMR BMI ≥27.5 યા ≥25 comorbidity—Western ≥30 સે lower.
- •Waist (>90 cm men, >80 cm women) thin-fat phenotype BMI જિતના matter South Asian.
- •Contraindications pregnancy, MTC/MEN2, severe pancreatitis—CDSCO labels BMI regardless.
- •Obesity pharmacotherapy સે પહલે 3–6 months lifestyle; GLP-1 cosmetic shortcut never.
T2D માં GLP-1 therapy કૌન qualify?
RSSDI lifestyle/metformin glycaemic targets fail—HbA1c >7–7.5% optimised care. CVD, heart failure, CKD, obesity, sulfonylurea hypoglycaemia favour. No single BMI diabetes; lean Indian T2D CVR/renal profile GLP-1. Age, kidney, concurrent meds selection. T1D, gestational without specialist, DKA not indicated. Diabetologist/endocrinologist HbA1c trends, glucose, complications before class. Schedule H prescription clinical criteria meet હોં યા ન હોં—always required.
India obesity criteria GLP-1?
ICMR/South Asia protocols BMI ≥27.5 no comorbidity medication consider, ≥25 comorbidity present. Below Western ≥30—Indians lower weights insulin resistance, fatty liver, CVR. Waist >90 men >80 women South Asians supplements BMI. Never first-line—3–6 months structured lifestyle first. Motivation, mental health, eating disorder, afford long-term assess. Cosmetic without metabolic not appropriate. BMI meet no lifestyle attempt—defer dietitian referral.
Thin-fat phenotype
South Asians common: apparently normal BMI high visceral fat low muscle—early metabolic disease.
Indian BMI thresholds Western સે ક્યોં અલગ?
Asian Indian phenotype Joshi et al.—higher visceral adiposity, insulin resistance, earlier T2D same BMI Caucasian. Chennai BMI 26 waist 92 cm > European BMI 28 metabolic risk. RSSDI/ICMR realities. Clinical judgement: marathon vegetarian BMI 27 no comorbidity vs sedentary executive BMI 27 prediabetes fatty liver different. Genetics, family, socioeconomic individual beyond population guidelines. WHO Asian BMI; ICMR most relevant patients.
BMI thresholds: Western vs India-aligned
- સંદર્ભ: Pharmacotherapy no comorbidity — Western: Often BMI ≥30 — India: Often BMI ≥27.5 (ICMR)
- સંદર્ભ: With comorbidity — Western: Often ≥27 — India: Often ≥25 with comorbidity
- સંદર્ભ: Waist focus — Western: Less — India: Central obesity central
- સંદર્ભ: Lifestyle first — Western: Recommended — India: Required 3–6 months (ICMR)
- સંદર્ભ: T2D indication — Western: Glycaemic — India: RSSDI after metformin uncontrolled
Common comorbidities earlier GLP-1 (BMI ≥25)
- Comorbidity: Prediabetes/elevated HbA1c — ક્યોં: Diabetes progression reduce; insulin sensitivity
- Comorbidity: Hypertension — Weight/glycaemic BP support
- Comorbidity: Dyslipidaemia — GLP-1 RA triglycerides/weight lipids improve
- Comorbidity: NAFLD/fatty liver — 5–10% weight hepatic steatosis reduce
- Comorbidity: Obstructive sleep apnoea — Weight apnoea severity improve
- Comorbidity: Established CVD — RSSDI high-risk diabetes GLP-1 favour
Comorbidities case strengthen GLP-1?
BMI beyond metabolic clustering weigh. Prediabetes central obesity, multi-agent hypertension, high triglycerides, NAFLD ultrasound, sleep apnoea lifestyle insufficient pharmacotherapy justify. PCOS insulin resistance endocrine discussion. Premature CVD/diabetes family borderline numbers risk framing. RSSDI CVR integration diabetes+heart disease algorithm earlier isolated mild obesity. Labs/imaging document not self-report. ICMR obesity chronic disease complications not cosmetic.
કૌન qualify નહીં/specialist review?
Contraindications pregnancy/breastfeeding; MTC/MEN2; severe pancreatitis. Caution severe gastroparesis, active IBD, frail elderly low BMI harmful weight loss. Untreated eating disorders psychiatric before appetite suppressants. Cannot monitor/afford sustained counsel alternatives. First-degree thyroid cancer careful endocrine eval. Kesho eligibility નહીં—physician full history/exam/investigations only. CDSCO label contraindications legally binding BMI regardless.
Medically reviewed
Dr. Ananya Mehta, MD, DM Endocrinology
Consultant Endocrinologist, India
This article has been reviewed by our medical advisory team, including endocrinologists, internal medicine specialists, and cardiologists, and is based on current scientific evidence and Indian clinical guidelines. Last reviewed: June 2026.
Last medically reviewed: Jun 26, 2026